Wegovy Click Counting: Why Published Charts Disagree and the Pen Type Matters

Educational review — November 4, 2026. Searching for a Wegovy click-count table produces an apparent shortcut: match a dose to a number. But even two handouts from the same Canadian clinic do not give identical numbers for the same high-strength pen. That discrepancy is the starting point for this article, not something to quietly round away.

The banner is a comparison of published claims, not a dosing chart. It concerns the 9.6 mg total-content FlexTouch pen at 3.2 mg/mL. It must not be used for a single-use pen, another strength, another brand of semaglutide or a different national presentation. Dose changes should be agreed with the prescriber and pharmacist.

What readers should know first

• Wegovy’s Canadian product information describes both single-use pens and multi-use FlexTouch pens.
• For FlexTouch, the manufacturer instructs users to select the displayed prescribed dose, not count clicks.
• The two clinic sources below differ for 0.5 mg and 1 mg targets. We are showing that disagreement, not selecting one set as correct.

A side-by-side audit of the published counts

The BCDiabetes Wegovy handout reports approximate off-label counts for its 9.6 mg pen discussion. A separate BCDiabetes comparison dated August 26, 2026 includes a Wegovy row with different values. “Not listed” means the particular source does not provide that target; it does not mean an injection should be attempted by inference.

Source 1: BCDiabetes Wegovy handout (listed Apr 25, 2026).Source 2: BCDiabetes semaglutide comparison (Aug 26, 2026).

DO NOT CHOOSE A DOSE FROM THIS COMPARISON. Novo Nordisk: use the dose counter, not the number of clicks.

The first handout states a 0.01 mL-per-click assumption. Under that assumption, a 3.2 mg/mL solution corresponds to 0.032 mg per modelled click. Thirty would therefore represent 0.960 mg and 31 would represent 0.992 mg; neither arithmetic result is exactly 1 mg. Likewise, 15 gives 0.480 mg and 16 gives 0.512 mg. This is our calculation to explain the discrepancy, not a calibration of an actual pen.

There is another important example: the first handout associates 50 clicks with approximately 1.7 mg, but its own stated volume assumption yields 1.6 mg. An editorial table should not silently turn that approximation into an exact dose claim. Nor should it silently replace the source’s number with a different count and call the result verified.

Identify the device before discussing a number

The Canadian Wegovy monograph lists FlexTouch pens with total contents of 1, 2, 4, 6.8 and 9.6 mg, corresponding to labelled per-dose strengths of 0.25, 0.5, 1, 1.7 and 2.4 mg. It includes two concentrations for the 2 mg total-content presentation. That alone makes a generic “Wegovy clicks” instruction insufficient. Authorized presentations are not a guarantee that every version is stocked locally.

For the multi-use device, the instructions say to use the dose counter and pointer and explicitly warn against setting a dose by counting clicks. The sounds can differ with the direction of turning. A single-use device has a different injection process; sounds during activation or completion are not selectable dose increments.

What an educational chart can—and cannot—establish

Three questions need separate answers. What did a source print? Is its arithmetic internally consistent? And has a particular device setting been validated to deliver the intended amount? We can verify the first by reading the original document and check the second by calculation. Neither step answers the third.

This is why a large, legible chart also needs a large, legible limitation. A cropped screenshot without the pen strength, date, source and warning can travel much farther than the surrounding explanation. The banner retains those details and links back to the source discussion. It is designed to make the uncertainty visible, not to lend an unofficial technique the appearance of manufacturer approval.

Practice guidance for pharmacists

ISMP has described communication and medication-record risks with click-counting instructions. Its 2025 article discusses US devices, so its statement about Wegovy single-use pens is not a complete description of Canadian presentations. Canadian counselling must use the patient’s actual pack and the Canadian instructions.

1. Check whether the pen is single-use or FlexTouch, then verify the per-dose strength, total contents and concentration.
2. Ask which chart the patient is using and retain its source and date when reconciling conflicting directions.
3. Do not treat a calculated value or a rounded handout entry as a manufacturer-validated setting.
4. Clarify any nonstandard directions with the prescriber and reconcile the label and medication record.
5. Discuss tolerability, affordability and available presentations without promising that stretching a pen is safe or economical.

What to do with a chart found online

Bring it to the pharmacy together with the carton and pen. Ask what product the chart describes, whether it conflicts with the supplied instructions and how the treatment plan should be documented. If a supposed precise chart cannot answer those questions, a clearer-looking version does not resolve the underlying problem. Until an individualized plan is confirmed, do not use this comparison to change a dose.